Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Faron Pharma to take Clevegen cancer candidate into the clinic this year

Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd (LON:FARN), spoke to Proactive's Andrew Scott following the release of their interim results.

He says he's looking forward to kicking off the first in-human trial of the firm’s Clevegen cancer candidate later this year.

Clevegen is one of a new generation of drugs that helps to weaken a tumour’s ability to suppress the human immune system.

The focus on oncology comes after disappointing Phase III top-line data from their lead drug, Traumakine for the condition called acute respiratory distress.

 
Meet Anglo Asian Mining PLC, Jersey Oil and Gas PLC, Europa Oil & Gas (Holdings) Plc, ANGLE plc and Eurasia Mining plc at our event, Dublin , 22 November 2018. Register here »
View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

Newswire
September 12 2018

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use